Market closed
Zomedica/$ZOM
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Zomedica
Zomedica Corp is a veterinary health company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians. The company's product portfolio includes diagnostics and therapeutics that emphasize patient health and practice health. The company is focused on the final development and commercialization of its TRUFORMA platform, which detects thyroid disorders in dogs & cats and adrenal disorders in dogs. Its operations are comprised of two reportable segments namely Diagnostic and Therapeutic Devices. It earns the majority of revenue from the therapeutics segment.
Ticker
$ZOM
Sector
Trading on
AMEX
Industry
Health Care Equipment & Supplies
Headquarters
Employees
144
Website
Zomedica Metrics
BasicAdvanced
$123M
Market cap
-
P/E ratio
-$0.06
EPS
1.06
Beta
-
Dividend rate
Price and volume
Market cap
$123M
Beta
1.06
52-week high
$0.23
52-week low
$0.12
Average daily volume
6.8M
Financial strength
Current ratio
10.822
Quick ratio
9.829
Long term debt to equity
0.712
Total debt to equity
1.024
Management effectiveness
Return on assets (TTM)
-9.78%
Return on equity (TTM)
-26.82%
Valuation
Price to revenue (TTM)
4.594
Price to book
0.61
Price to tangible book (TTM)
1.16
Price to free cash flow (TTM)
-3.974
Growth
Revenue change (TTM)
11.33%
Earnings per share change (TTM)
316.53%
3-year revenue growth (CAGR)
701.03%
3-year earnings per share growth (CAGR)
0.26%
What the Analysts think about Zomedica
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Zomedica stock.
Zomedica Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Zomedica Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Zomedica News
AllArticlesVideos
Zomedica Launches Two New Quantitative Assays on the TRUFORMA(R) Platform: Canine NT-proBNP and Progesterone
Accesswire·13 hours ago
Zomedica Appoints Scott A. Jordan Executive Vice President, Finance & Chief Financial Officer
Accesswire·5 days ago
Zomedica to Present at the NobleCon20 Twentieth Annual Emerging Growth Equity Conference December 4, 2024
Accesswire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Zomedica stock?
Zomedica (ZOM) has a market cap of $123M as of December 24, 2024.
What is the P/E ratio for Zomedica stock?
The price to earnings (P/E) ratio for Zomedica (ZOM) stock is 0 as of December 24, 2024.
Does Zomedica stock pay dividends?
No, Zomedica (ZOM) stock does not pay dividends to its shareholders as of December 24, 2024.
When is the next Zomedica dividend payment date?
Zomedica (ZOM) stock does not pay dividends to its shareholders.
What is the beta indicator for Zomedica?
Zomedica (ZOM) has a beta rating of 1.06. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.